IRRAS Strengthens Executive and Commercial Teams with Appointments of Karl-Matthias Moehlmann and Klemens Fölling

LA JOLLA, Calif., LAICHINGEN, Germany and STOCKHOLM, Sept. 13, 2017 /PRNewswire/ — IRRAS, a commercial-stage medical technology company developing breakthrough devices for a broad range of intracranial bleeding applications and procedures, today announced two key appointments to its executive and commercial teams: Karl-Matthias Moehlmann as Senior Vice President Commercial Operations, General Manager Europe and a member of the executive management team and Klemens Fölling as Director of International Sales.

Collectively, Mr. Moehlmann and Mr. Fölling bring over 40 years of experience in developing, launching, marketing and selling medical devices for neurological applications. Prior to their appointments as full-time employees, Mr. Moehlmann and Mr. Fölling served as senior advisors to IRRAS.

“I am very pleased to have both Matthias and Klemens join the IRRAS team,” said Kleanthis G. Xanthopoulos, Ph.D., Chairman and CEO of IRRAS. “Matthias’ executive management experience, marketing expertise and proven commercial track record in medical devices, coupled with Klemens’ vast experience in neurological product sales, will assist IRRAS to achieve our major commercial growth milestones for our products based on our IRRAflow® technology.”

Mr. Moehlmann added, “The treatment of intracranial bleedings and life-threatening hemorrhagic strokes has not advanced during the last two decades and innovation is desperately needed. The IRRAflow product is a first-in-class device that provides an elegant solution for these patients with less invasiveness and more efficacy. I am truly excited to join the IRRAS team and look forward to advancing our platform of medical devices to transform the field of neurosurgery.”

Mr. Moehlmann brings more than fifteen years of experience as an executive or advisor for leading medical device companies in the neurological, trauma and orthopedic categories to IRRAS. Prior to joining IRRAS, Mr. Moehlmann was Director of Marketing at Kyphon B.v.B.a, (acquired by Medtronic) and was VP of Business Development at Bonesupport AB. Prior to that, Mr. Moehlmann held leadership and consultancy roles at aap Bioimplants, Benvenue Medical, CRA DePuy Spine, X-Spine, Miedke Hydrocephalus Solutions and Mimedx Biologics. He holds a M.Sc. in Biochemistry from University of Hanover, an M.B.A in Economics and Master of Public Health from the University of Graz.

Mr. Fölling has amassed more than 25 years of neurosurgery and spinal device sales, holding key national and international sales positions at Olympus Medical, B.Braun Aesculap, Medtronic and Simpirica Spine. Throughout his career, Mr. Fölling has implemented sales structures in direct and distributor businesses worldwide in over 20 countries and has established relationships with neurosurgical key opinion leaders (KOLs) in Europe which will be beneficial to IRRAS. Mr. Fölling received his B.A degree from Münster University.

About IRRAflow

IRRAS has developed and commercialized a revolutionary intelligent brain fluid management device stemming from its core IRRAflow technology that addresses the complications associated with the occurrence of hemorrhagic stroke. Currently available devices do not address the complications that lead to death because they do not prevent occlusion (or blockage) in the catheter during treatment and they do not accurately monitor intracranial pressure (ICP). IRRAS’ products provide a transformative solution for stroke and hematoma patients with less invasiveness and more efficacy, through the integration of aspiration, targeted infusion and intracranial pressure monitoring in a single robust device.

About IRRAS

IRRAS AB is a commercial-stage medical technology company formed to develop and commercialize breakthrough devices for a broad range of intracranial bleeding applications and procedures. IRRAflow is the company’s flagship commercial medical device that provides intelligent, dynamic control of CNS fluids to address the complications associated with the occurrence of hemorrhagic stroke. With its unique product portfolio, protected by key intellectual property patents and patent applications, IRRAS is well-positioned to improve patient outcomes and establish a leadership position in the medical device market. IRRAS is operational in Sweden and Germany with corporate headquarters in La Jolla, CA, USA. For more information, please visit www.irras.com.

CONTACT:
Amy Conrad
Juniper Point
858-914-1962

IRRAS Appoints Fredrik Alpsten as Chief Financial Officer and Deputy CEO

-Mr. Alpsten will Lead the Development of IRRAS’ Global Finance Strategies-

Stockholm, Sweden August 30, 2017 – IRRAS, a commercial-stage medical technology company developing breakthrough devices for a broad range of intracranial bleeding applications and procedures, today announced the appointment of Fredrik Alpsten as Chief Financial Officer and Deputy Chief Executive Officer and a member of the executive management team. Mr. Alpsten brings approximately 20 years of operational, financial, and strategic business experience as an executive in the medical technology field. In his new role, Mr. Alpsten will report directly to the CEO of IRRAS, Kleanthis G. Xanthopoulos, Ph.D., from the Stockholm, Sweden site. IRRAS expects Mr. Alpsten to join during early 2018 at the latest.

“We are very pleased to welcome Fredrik to the executive team of IRRAS,” said Kleanthis G. Xanthopoulos, CEO of IRRAS. “Over the last two decades, Fredrik has amassed a deep understanding of the healthcare industry, having served as both a public company CEO and CFO, and his breadth of experience in operations, finance, and strategy are well suited to help advance IRRAS to the next phase of the company’s growth.”

Mr. Alpsten commented, “IRRAS is an exciting company with a unique combination of intelligent medical device and drug delivery technology, world-renowned thought leaders in neurosurgery, and a proven leadership team. The opportunity to work at a company that has commercialized an innovative medical device to treat hemorrhagic strokes and the possibility to develop additional transformative products is very attractive. I am excited to join the company and help bring the IRRAflow® technology to patients in need across the globe.”

Most recently, Mr. Alpsten, as a member of the executive management team, served as Senior Vice President and CFO of Boule Diagnostics AB (Boule), a Swedish publicly-traded diagnostics company. During his six years in this role, Mr. Alpsten was responsible for overseeing multiple global departments including finance, investor relations, administration, IT, legal, human resources, and facilities. During his time at Boule, Mr. Alpsten also served as President and CEO of Clinical Diagnostic Solutions Inc., a US subsidiary of Boule. Prior to that, for three years he was President and CEO of Doxa AB (Doxa), a publicly-traded medical technology company located in Sweden, where he grew the company from a research and development company to commercial-stage marketing organization with a robust sales presence in the EU and the US. Before serving as President and CEO at Doxa, Mr. Alpsten was VP, CFO of Doxa for eight years and prepared the company for an Initial Public Offering on the Nasdaq exchange. Mr. Alpsten also served as Finance Director of N&T Argonaut AB, a publicly-traded company on the Stockholm Stock Exchange, for nine years.

In addition to different board assignments for the Boule group, Mr. Alpsten currently serves as Chairman of the Board of Personlig Almanacka Nordic AB and board member and chairman of the audit committee of Oniva Online Group Europe AB. Mr. Alpsten received a Master of Science degree from the Stockholm School of Economics.

About IRRAflow
IRRAS has developed and commercialized a revolutionary intelligent brain fluid management device stemming from its core IRRAflow technology that addresses the complications associated with the occurrence of hemorrhagic stroke. Currently available devices do not address the complications that lead to death because they do not prevent occlusion (or blockage) in the catheter during treatment and they do not accurately monitor intracranial pressure (ICP). IRRAS’ products provide a transformative solution for stroke and hematoma patients with less invasiveness and more efficacy, through the integration of aspiration, targeted infusion and intracranial pressure monitoring in a single robust device.

About IRRAS
IRRAS AB is a commercial-stage medical technology company formed to develop and commercialize breakthrough devices for a broad range of intracranial bleeding applications and procedures. IRRAflow is the company’s flagship commercial medical device that provides intelligent, dynamic control of CNS fluids to address the complications associated with the occurrence of hemorrhagic stroke. With its unique product portfolio, protected by key intellectual property patents and patent applications, IRRAS is well-positioned to improve patient outcomes and establish a leadership position in the medical device market. IRRAS is operational in Sweden and Germany with corporate headquarters in La Jolla, CA, USA.

IRRAS Appoints Medical Technology Leader C. Lance Boling as Vice President, Product Development

-C. Lance Boling to Spearhead Global Expansion of IRRAflow® Technology Portfolio-

La Jolla, CA, USA and Stockholm, Sweden April 10, 2017 – IRRAS, a commercial-stage medical technology company developing breakthrough devices for a broad range of brain pathology therapeutic applications and procedures, today announced the appointment of C. Lance Boling as Vice President, Product Development and a member of the executive management team. Mr. Boling brings over 25 years of experience in medical device development, manufacturing, and operations to IRRAS, where he will be responsible for expanding the IRRAflow technology portfolio in both the EU and U.S. In his role, Mr. Boling will report directly to the Chairman and CEO of IRRAS, Kleanthis G. Xanthopoulos, Ph.D., from one of the company’s U.S. sites.

“I am excited to welcome Lance as a member of the IRRAS executive management team as we expand our commercial footprint and advance our IRRAflow technology,” said Kleanthis G. Xanthopoulos, Ph.D., Chairman and CEO of IRRAS. “Lance has very impressive credentials – in addition to his deep medical device development expertise, he also brings valuable manufacturing and operations experience that will greatly enhance our ability to transform the way strokes and brain hematomas are treated.”

“Each year in the U.S. and EU, approximately two million people suffer strokes and almost three hundred thousand have a hemorrhagic stroke, with almost half of these instances ending in death. Unfortunately, the current available medical devices cannot address the complications that lead to death and the need for innovation in this field is urgent,” said C. Lance Boling, Vice President, Product Development of IRRAS. “Because of this, I am extremely pleased to join the IRRAS team to combat this global health issue. We plan to aggressively expand and advance our core IRRAflow technology to provide patients, physicians and payors with an intelligent solution for the management of strokes and brain hematomas.”

Prior to joining IRRAS, Mr. Boling was Director of Nano Technology Development at Abbott Laboratories where he was responsible for leading numerous development efforts from inception through commercialization. Before Abbott, Mr. Boling held leadership positions at Nanostim, Nevro Corporation, NeuroPace, Inc., and Autonomic Technology. Mr. Boling holds a BA in Business Management from the University of Phoenix and has participated in Post Graduate studies in Manufacturing Technology at Stanford University. He holds over 40 pioneering patents – granted and pending in the medical device industry – and is a regular guest lecturer on product development at local universities and high schools.

About IRRAflow
IRRAS has developed and commercialized a revolutionary catheter device stemming from its core IRRAflow technology that addresses the complications associated with the occurrence of hemorrhagic stroke. According to the WHO, there are 15 million stroke patients annually and complications from these strokes result in more than 6 million annual deaths, almost 1 every 10 seconds. Currently available devices do not address the complications that lead to death because they do not prevent occlusion (or blockage) in the catheter during treatment and they do not accurately monitor intracranial pressure (ICP). IRRAS’ clinical strategy is to provide a transformative solution for stroke and hematoma patients with less invasiveness and more efficacy, through the integration of aspiration, targeted infusion and intracranial pressure monitoring in a single robust device.

About IRRAS
IRRAS AB is a commercial-stage medical technology company formed to develop and commercialize breakthrough devices for a broad range of brain pathology therapeutic applications and procedures. IRRAflow is the company’s flagship commercial medical device that provides intelligent, dynamic control of CNS fluids to address the complications associated with the occurrence of hemorrhagic stroke. With its unique product portfolio, protected by key intellectual property patents and patent applications, IRRAS is well-positioned to improve patient outcomes and establish a leadership position in the medical device market. IRRAS is operational in Germany and La Jolla, CA, USA with corporate headquarters in Stockholm, Sweden. For more information, please visit www.irras.com.

Contact:
Amy Conrad
1-858-914-1962
amy@juniper-point.com

IRRAS AB Closes Financing Round to Establish IRRAflow™ as Leading CNS Fluid Management Device

-Expanding commercialization in Germany and operations in the US to advance flagship technology-

LA JOLLA, Calif. and STOCKHOLM, May 11, 2016 /PRNewswire/ — IRRAS AB, a commercial-stage medical technology company developing breakthrough devices for a broad range of brain pathology therapeutic applications and procedures, today announced the completion of a pivotal round of financing that will support IRRAS’ EU commercial growth strategy and receive regulatory approval in the US to become a global leader in CNS fluid management in the medical device space. The raise totaled SEK $91.25M or $11.25M with participation from Serendipity/Ixora, and The Vandel Group, as well as recognized high net-worth healthcare investors in Sweden.

IRRAS has successfully started the commercialization of IRRAflow® and has performed more than 60 different cases globally. Proceeds from the recent financing will be used to establish operations in the United States (US), broaden commercialization of IRRAflow in Germany and additional key EU markets with the goal to become profitable by 2018. IRRAS also plans to aggressively pursue expansion opportunities for IRRAflow in abdominal, thoracic, and orthopedic applications, including targeted drug delivery.

“The number one cause of disability in the world is complications associated with strokes. IRRAS is focused on the treatment of hemorrhagic strokes that constitute about fifteen percent of all strokes but account for over forty percent of stroke associated deaths,” said Kleanthis G. Xanthopoulos, Ph.D., Executive Chairman and acting CEO of IRRAS. “This is a global health problem that results in immense financial stress to the healthcare system. Our proprietary, commercial product, IRRAflow, can help address these serious brain pathologies and provide patients with improved solutions with less invasiveness, more efficacy, and continuous ICP monitoring that will hopefully translate into saved lives. To help us do this, the recently completed over-subscribed financing round will enable IRRAS to expand its commercial operations and opportunities with IRRAflow and transform the management of CNS fluid.”

IRRAS has developed and commercialized a revolutionary catheter device stemming from its core IRRAflow technology that addresses the complications associated with the occurrence of hemorrhagic stroke. According to the WHO, there are 15 million stroke patients annually and complications from these strokes result in more than 6 million annual deaths, almost 1 every 10 seconds. Currently available devices do not address the complications that lead to death because they cannot address occlusion (or blockage) in the catheter during treatment and they do not accurately monitor intracranial pressure (ICP). IRRAS’ clinical strategy is to provide a significantly improved solution for stroke and hematoma patients with less invasiveness and more efficacy, through the integration of aspiration, targeted infusion and intracranial pressure monitoring in a single robust device.

About IRRAS
IRRAS AB is a commercial-stage medical technology company formed to develop and commercialize breakthrough devices for a broad range of brain pathology therapeutic applications and procedures. IRRAflow is the company’s flagship commercial medical device that provides intelligent, dynamic control of CNS fluids to address the complications associated with the occurrence of hemorrhagic stroke. With its unique product portfolio, protected by key intellectual property patents and patent applications, IRRAS is well-positioned to improve patient outcomes and establish a leadership position in the medical device market. IRRAS is operational in Germany and La Jolla, USA with corporate headquarters in Stockholm, Sweden. For more information, please visit www.irras.com.

Contact:
Amy Conrad
1-858-914-1962
amy@juniper-point.com

IRRAS AB Appoints Anders P. Wiklund to its Board of Directors

Mr. Wiklund is a well recognized and seasoned healthcare executive

 
STOCKHOLM and LA JOLLA, Calif., March 23, 2016 /PRNewswire/ — IRRAS AB, a commercial stage medical technology company pioneering breakthrough devices to meet the challenges of fluid control and management for a broad range of CNS therapeutic applications and procedures, today announced the appointment of Anders P. Wiklund to its Board of Directors. The majority shareholders of IRRAS have endorsed Mr. Wiklund’s board membership, which will be formalized at the company’s upcoming shareholder meeting in April. Mr. Wiklund, a pharmacist by training, is an accomplished industry leader with expertise in operations, strategy, corporate development, and fund raising in both the United States and Europe. Among other appointments Mr. Wiklund was President & CEO of KabiVitrum Inc., KabiPharmacia Inc., President of Pharmacia Development Corp and co-founder of Esperion Therapeutics.

“Anders brings to IRRAS a rare combination of corporate development expertise, proven business acumen, and international executive leadership demonstrated over four decades,” said Kleanthis G. Xanthopoulos, Ph.D., Executive Chairman and acting CEO of IRRAS. “We look forward to his contributions as we implement our clinical, commercial and operational goals to establish IRRAS as a leading medical device company.”

“I am very pleased to be joining the Board of IRRAS,” commented Mr. Wiklund. “IRRAS is an attractive company with high potential, innovative first-in-class devices like IRRAflow®, passionate team members and an evolving product strategy with global market opportunities. IRRAS is positioned for the next stage of development and I am excited about contributing to its future.”

Mr. Wiklund has accumulated a wealth of operational, business development, and strategic advisory experience from his long-standing career in the biotechnology and pharmaceutical industries in Europe and the United States. Most notably, Mr. Wiklund spent 29 years with the Kabi and Pharmacia group of companies, where he held a number of executive level positions, such as Managing Director of KabiVitrum in the UK, President of KabiVitrum International in Sweden, President and CEO of KabiVitrum and KabiPharmacia in the United States. Mr. Wiklund also currently serves on the boards of EffRx Pharmaceuticals SA, where he is Chairman, Life Medical AB and Inspirion Delivery Technologies. Mr. Wiklund holds a Master of Pharmacy from the Pharmaceutical Institute, Stockholm, Sweden and studied business administration at the University of Stockholm.

Mr. Wiklund joins Kleanthis G. Xanthopoulos, Ph.D., Executive Chairman and acting CEO of IRRAS, Christos Panotopoulos, M.D., Ph.D., Chief Medical Officer of IRRAS, Saeid Esmaeilzadeh, Ph.D., CEO of Serendipity Innovations and founder of several innovative life sciences, medical technology and clean technology companies, and Marios Fotiadis, M.B.A., CEO of the Vandel Group.

About IRRAS
IRRAS AB is a commercial stage medical technology company formed to develop and commercialize breakthrough devices for a broad range of brain pathology therapeutic applications and procedures. IRRAS was founded in 2012 by a leading neurosurgeon with the goal to introduce innovative devices for brain surgery. IRRAflow is the company’s flagship commercial medical device that provides intelligent, dynamic control of CNS fluids. The company’s products are protected by key intellectual property patents and patent applications. With its unique product development expertise, qualified investors and globally recognized board and clinical advisors, IRRAS is well-positioned to improve patient outcomes and establish a leadership position in the medical device market. IRRAS is operational in Germany and San Diego, USA with corporate headquarters in Stockholm, Sweden. For more information, please visit www.irras.com.

Contact:
Amy Conrad
1-858-914-1962
amy@juniper-point.com

Irras Radio Irras Academy

At IRRAS, your privacy and the protection of your personal data are important to us. To ensure GDPR compliance, this website does not store or track any personal information, including Google Analytics or form submission data.
By using the website, you acknowledge and accept our policy.